We are bringing you updates on COVID-19. Note: If you are listening to these more than a few days in the future, please beware that information may have changed and check subsequent episodes. This episode was recorded May 30, 2020
In the wake of the ACTT-1 trial on remdesivir (see post), enthusiasm has quickly grown. In this podcast we review Goldman et al, a Gilead funded study, looking at duration of treatment (not efficacy of remdesivir itself).
